Precision Medicine

Researchers Engineer Stable FGF1 to Boost Healing and Metabolism
Biotech & Bioprocessing Researchers Engineer Stable FGF1 to Boost Healing and Metabolism

A single targeted mutation known as R126E has proven capable of enhancing the potency of growth-promoting proteins while making them more resistant to chemical degradation. This finding comes at a time when regenerative medicine is seeking more durable solutions for patients with impaired healing

How Is Tech Transforming Biopharmaceutical Innovation?
Tech & Innovation How Is Tech Transforming Biopharmaceutical Innovation?

The convergence of legacy manufacturing expertise and cutting-edge molecular platforms is fundamentally transforming the current biopharmaceutical landscape. This paradigm shift marks the end of an era defined by slow, incremental improvements and the beginning of a highly synchronized digital age.

VA Tests Semaglutide as a New Treatment for Alcoholism
Research & Development VA Tests Semaglutide as a New Treatment for Alcoholism

VA leadership has issued a cautionary warning against the off-label use of GLP-1 medications for alcoholism without strict medical supervision and oversight. This directive arrives just as the Charles George VA Medical Center in Asheville, North Carolina, spearheads a transformative Phase 3

New AI Model Identifies Aggressive Prostate Cancer Variants
Tech & Innovation New AI Model Identifies Aggressive Prostate Cancer Variants

Advanced algorithms are now capable of correlating visual cellular patterns on pathology slides with specific gene-expression profiles linked to aggressive disease. This breakthrough in digital pathology allows clinicians to look beyond the surface level of tissue samples to understand the

Can Merck and SCRI Bridge the Gap in Oncology Trials?
Research & Development Can Merck and SCRI Bridge the Gap in Oncology Trials?

The strategic alliance between Merck and the Sarah Cannon Research Institute aims to transform oncology research by deploying a network of over 200 locations and 1,500 oncology physicians. This massive undertaking addresses a fundamental imbalance in modern medicine: while nearly eighty-five

Japan Approves Sevabertinib for HER2-Mutant Lung Cancer
Research & Development Japan Approves Sevabertinib for HER2-Mutant Lung Cancer

The SOHO-01 trial results highlight that gastrointestinal and skin-related issues such as diarrhea and rash are the most common side effects, which are generally considered manageable by clinicians. On August 24, 2026, Japan’s Ministry of Health, Labour and Welfare reached a landmark decision by

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later